Suzhou Novoprotein Scientific Stock Fundamentals
| 688137 Stock | 34.62 0.17 0.49% |
Suzhou Novoprotein Scientific fundamentals help investors to digest information that contributes to Suzhou Novoprotein's financial success or failures. It also enables traders to predict the movement of Suzhou Stock. The fundamental analysis module provides a way to measure Suzhou Novoprotein's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Suzhou Novoprotein stock.
At present, Suzhou Novoprotein's Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 32 M, whereas Tax Provision is projected to grow to (6.3 M). Suzhou | Select Account or Indicator |
Suzhou Novoprotein Scientific Company Current Valuation Analysis
Suzhou Novoprotein's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Suzhou Novoprotein Current Valuation | 1.83 B |
Most of Suzhou Novoprotein's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Suzhou Novoprotein Scientific is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Suzhou Novoprotein Scientific has a Current Valuation of 1.83 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all China stocks is notably lower than that of the firm.
Suzhou Novoprotein Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Suzhou Novoprotein's current stock value. Our valuation model uses many indicators to compare Suzhou Novoprotein value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Suzhou Novoprotein competition to find correlations between indicators driving Suzhou Novoprotein's intrinsic value. More Info.Suzhou Novoprotein Scientific is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Suzhou Novoprotein by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Suzhou Novoprotein's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Suzhou Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Suzhou Novoprotein's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Suzhou Novoprotein could also be used in its relative valuation, which is a method of valuing Suzhou Novoprotein by comparing valuation metrics of similar companies.Suzhou Novoprotein is currently under evaluation in current valuation category among its peers.
Suzhou Fundamentals
| Return On Equity | -0.0099 | ||||
| Return On Asset | -0.0228 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | 0.58 % | ||||
| Current Valuation | 1.83 B | ||||
| Shares Outstanding | 70.18 M | ||||
| Shares Owned By Insiders | 72.80 % | ||||
| Shares Owned By Institutions | 5.55 % | ||||
| Price To Book | 1.14 X | ||||
| Price To Sales | 17.91 X | ||||
| Revenue | 153.19 M | ||||
| Gross Profit | 228.37 M | ||||
| EBITDA | (71.71 M) | ||||
| Net Income | 12.84 M | ||||
| Total Debt | 11.08 M | ||||
| Book Value Per Share | 29.05 X | ||||
| Cash Flow From Operations | 69.16 M | ||||
| Earnings Per Share | (0.31) X | ||||
| Number Of Employees | 579 | ||||
| Beta | 2.14 | ||||
| Market Capitalization | 2.41 B | ||||
| Total Asset | 2.3 B | ||||
| Retained Earnings | 149.52 M | ||||
| Working Capital | 2.02 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 2.3 B | ||||
| Last Dividend Paid | 0.5 |
About Suzhou Novoprotein Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Suzhou Novoprotein Scientific's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Suzhou Novoprotein using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Suzhou Novoprotein Scientific based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 153.2 M | 187.9 M | |
| Cost Of Revenue | 37.3 M | 37.1 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Suzhou Stock
Suzhou Novoprotein financial ratios help investors to determine whether Suzhou Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Suzhou with respect to the benefits of owning Suzhou Novoprotein security.